This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

Informa
Menu
Key Sessions
Keiichi Masuya, PhD
Various Therapeutic Applications from PeptiDream: Recent Advancements of Peptide-drug Conjugates
PeptiDream, Inc.
Muthiah (Mano) Manoharan, PhD
Crossing the Barriers and Boundaries I: Delivery of RNAi Therapeutics
Alnylam Pharmaceuticals, Inc.
Takanori Yokota, MD, PhD
New Stage of DNA/RNA Heteroduplex Oligonucleotide
Tokyo Medical and Dental University
Barry Greene
Crossing the Barriers and Boundaries II: Towards Global Approval for Onpattro and other RNAi Therapeutics
Alnylam Pharmaceuticals
keyboard_arrow_right

Conference Day One

keyboard_arrow_leftSearch & Filter
search

Conference Day One

search
8:00am - 9:00am60 mins
Registration and Coffee
    9:00am - 10:30am90 mins
    Workshop #1: Path to a Successful IND/IMPD for Oligonucleotide Therapeutics
    Part 1: Nonclinical Perspective
    • Jennifer Lockridge, PhD - Senior Vice President, Program Development, Dicerna Pharmaceuticals, Inc.
    9:00am - 9:15am15 mins
    Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties
    Workshop Moderator’s Opening Remarks
    • Bruce Morimoto, PhD - Vice President, Drug Development, Cerecin
    9:15am - 9:45am30 mins
    Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties
    An Overview of Peptide Drug Development and Factors for Success
    • Bruce Morimoto, PhD - Vice President, Drug Development, Cerecin
    9:45am - 10:45am60 mins
    Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties
    Introduction to General Side Reactions in Peptide Synthesis and Prediction of Peptide Drug Chemical Stability
    • Yi Yang, Ph.D. - Senior Research Scientist, Chemical Development &, Ferring Pharmaceuticals A/S
    10:30am - 10:45am15 mins
    Workshop #1: Path to a Successful IND/IMPD for Oligonucleotide Therapeutics
    Q&A for Part 1
    • Jennifer Lockridge, PhD - Senior Vice President, Program Development, Dicerna Pharmaceuticals, Inc.
    10:45am - 11:15am30 mins
    Networking Refreshment Break
      11:15am - 12:30pm75 mins
      Workshop #1: Path to a Successful IND/IMPD for Oligonucleotide Therapeutics
      Part 2: CMC Perspective
      • G. Susan Srivatsa, PhD - President, ElixinPharma
      11:15am - 12:00pm45 mins
      Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties
      Prolonging Peptide Half-Life with Modifications (PEG, Lipid) and Implications for Manufacturing
      • Robert Hagopian - Director Business Development, PolyPeptide Group
      12:00pm - 12:45pm45 mins
      Workshop #2: Current Topics in Peptide Discovery and Development: A Focus on Improving Peptide Properties
      An Overview of Peptides and Immunogenicity
      • Brian Roberts, PhD - Associate Scientific Director of Protein Therapeut, Epivax
      12:30pm - 12:45pm15 mins
      Workshop #1: Path to a Successful IND/IMPD for Oligonucleotide Therapeutics
      Q&A for Part 2
      • G. Susan Srivatsa, PhD - President, ElixinPharma
      12:45pm - 12:50pm5 mins
      Close of Workshops
        2:00pm - 2:05pm5 mins
        Main Conference Plenary Keynote Session
        Chairperson’s Remarks
          2:05pm - 2:40pm35 mins
          Main Conference Plenary Keynote Session
          Crossing the Barriers and Boundaries I: Delivery of RNAi Therapeutics
          • Muthiah (Mano) Manoharan, PhD - Senior Vice President of Drug Discovery, Alnylam Pharmaceuticals, Inc.
          2:40pm - 3:15pm35 mins
          Main Conference Plenary Keynote Session
          Crossing the Barriers and Boundaries II: Towards Global Approval for Onpattro and other RNAi Therapeutics
          • Barry Greene - President, Alnylam Pharmaceuticals
          3:15pm - 3:50pm35 mins
          Networking Refreshment Break
            3:50pm - 4:25pm35 mins
            Main Conference Plenary Keynote Session
            Various Therapeutic Applications from PeptiDream: Recent Advancements of Peptide-drug Conjugates
            • Keiichi Masuya, PhD - Executive Vice President, PeptiDream, Inc.
            4:25pm - 5:00pm35 mins
            Main Conference Plenary Keynote Session
            New Stage of DNA/RNA Heteroduplex Oligonucleotide
            • Takanori Yokota, MD, PhD - Professor, Neurology and Neurological Science, Tokyo Medical and Dental University
            5:00pm - 6:00pm60 mins
            Close of Day One
              NextConference Day Two

              Get the latest news.
              As it happens

              Sign up to get the latest on the agenda and speakers.
              Filter
              Streams
              Choose Day